Delve Bio Launches Genomic Infectious Disease Test Delve Detect
Delve Bio’s Delve Detect is a metagenomic sequencing test capable of quickly identifying over 68,000 pathogens from CSF.
Read MorePosted by Andy Lundin | Dec 4, 2024 | Sequencing Systems |
Delve Bio’s Delve Detect is a metagenomic sequencing test capable of quickly identifying over 68,000 pathogens from CSF.
Read MorePosted by Andy Lundin | Sep 4, 2024 | Company News |
QIAGEN and AstraZeneca will develop a genotyping assay for companion diagnostics, advancing testing for therapies targeting chronic diseases.
Read MorePosted by Andy Lundin | May 20, 2024 | Infectious Diseases |
The Karius Test, a diagnostic tool for lung infections in immunocompromised patients, received Breakthrough Device Designation from the FDA.
Read MorePosted by Andy Lundin | Apr 17, 2024 | Infectious Diseases |
Delve Bio announced data on the use of mNGS for the definitive diagnosis of infectious causes of meningitis and/or encephalitis.
Read MorePosted by Andy Lundin | Oct 20, 2023 | Diagnostic Technologies, Gastrointestinal Infections |
Laboratory services company PathAI Diagnostics unveiled an AI-assisted LDT for the histologic scoring and staging of MASLD and MASH.
Read More